Stokol Tracy, Schaefer Deanna M, Shuman Martha, Belcher Nicole, Dong Lynn
Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.
Vet Clin Pathol. 2015 Mar;44(1):79-93. doi: 10.1111/vcp.12227. Epub 2014 Dec 26.
Immunophenotyping has replaced cytochemical staining as the preferred technique for classifying acute leukemia. However, some acute myeloid leukemias (AML) lack lineage-associated markers. In our experience, alkaline phosphatase (ALP) is expressed in immature canine monocytes. We hypothesized that ALP is a useful marker for monocytic AML.
The objective was to compare ALP expression in neoplastic cells from dogs with lymphoma, chronic lymphocytic leukemia (CLL), acute lymphoid leukemia (ALL), and AML.
Alkaline phosphatase results were retrieved from medical records of dogs with acute leukemia. Smears from dogs with lymphoma or leukemia were also prospectively stained for ALP activity. CLL was based on persistent lymphocytosis (10 × 10(9) /L) and acute leukemia on ≥ 20% blasts in blood or bone marrow. ALL was classified based on positive phenotyping for T- or B-lymphocyte antigens, and AML on positive phenotyping for CD11b, CD11c or CD14, or cytochemical staining for chloroacetate esterase, Sudan Black B, or myeloperoxidase.
There was no ALP activity in all 49 lymphomas and 7 CLLs. Weak ALP activity was seen in 31% of 14 ALL (all T-ALL). ALP activity was seen in all 20 AML (P < .001 vs ALL) with strong activity in 64% (vs 25% ALL) in most neoplastic cells (median 75% vs 9% ALL, P = .020). Of AML, 80% were CD34+ (vs 39% ALL, P = .027) and 100% were MHCII- (vs 43% ALL, P = .002).
ALP activity may be useful for AML confirmation in dogs, particularly if neoplastic cells only express CD34+ on immunophenotyping.
免疫表型分析已取代细胞化学染色,成为急性白血病分类的首选技术。然而,一些急性髓系白血病(AML)缺乏谱系相关标志物。根据我们的经验,碱性磷酸酶(ALP)在未成熟犬单核细胞中表达。我们假设ALP是单核细胞性AML的一种有用标志物。
目的是比较患有淋巴瘤、慢性淋巴细胞白血病(CLL)、急性淋巴细胞白血病(ALL)和AML的犬的肿瘤细胞中ALP的表达情况。
从患有急性白血病的犬的病历中获取碱性磷酸酶检测结果。对患有淋巴瘤或白血病的犬的涂片也进行了ALP活性的前瞻性染色。CLL基于持续性淋巴细胞增多(10×10⁹/L),急性白血病基于血液或骨髓中≥20%的原始细胞。ALL根据T或B淋巴细胞抗原的阳性表型进行分类,AML根据CD11b、CD11c或CD14的阳性表型或氯乙酸酯酶、苏丹黑B或髓过氧化物酶的细胞化学染色进行分类。
49例淋巴瘤和7例CLL均无ALP活性。14例ALL中有31%(均为T-ALL)可见弱ALP活性。20例AML均可见ALP活性(与ALL相比,P<0.001),大多数肿瘤细胞中64%(与ALL的25%相比)有强活性(中位数75%与ALL的9%相比,P=0.020)。AML中,80%为CD34+(与ALL的39%相比,P=0.027),100%为MHCII-(与ALL的43%相比,P=0.002)。
ALP活性可能有助于犬AML的确诊,特别是在肿瘤细胞在免疫表型分析中仅表达CD34+的情况下。